人妻中文字幕无码系列,日韩精品无码中午字幕

Cisplatin試劑返回列表頁

參考價:￥420 - ￥1100

具體成交價以合同協(xié)議為準

型號
HY-17394
品牌
MCE
廠商性質(zhì)
代理商
所在地
杭州市

規(guī)格

100 mg 420元 10000支可售

500 mg 1100元 10000支可售

在線詢價加入對比查看聯(lián)系電話

聯(lián)系方式：鄧女士查看聯(lián)系方式

更新時間：2023-05-22 14:03:33瀏覽次數(shù)：218次

聯(lián)系我時，請告知來自制藥網(wǎng)

產(chǎn)地	進口	級別	其他

生物活性

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy^[1]^[2]^[3].

IC₅₀ & Target

DNA Alkylator/Crosslinker^[1]

體外研究
(In Vitro)

Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK^[1].
Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight^[3].
Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively^[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00098995	Peter MacCallum Cancer Centre, Australia\|National Cancer Institute (NCI)	Cervical Cancer	December 2004	Phase 1
NCT01616849	Sun Yat-sen University\|Fujian Cancer Hospital\|First People′s Hospital of Foshan\|People′s Hospital of Guangxi\|Guangxi Medical University\|Guangzhou Medical University\|Hubei Cancer Hospital\|Hunan Provincial Cancer Hospital\|Hangzhou Cancer Hospital\|Wuhan Union Hospital, China\|Tongji Hospital\|Jiangxi Provincial Cancer Hospital\|Affiliated Cancer Hospital of Shantou University Medical College\|Wuhan University\|Zhejiang Cancer Hospital	Stage IV Nasopharyngeal Carcinoma	May 2012	Phase 2
NCT01846390	Canadian Cancer Trials Group\|Celgene	Peripheral T-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma	April 30, 2013	Phase 1

分子量

300.05

性狀

Solid

Formula

Cl₂H₆N₂Pt

CAS 號

15663-27-1

中文名稱

運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性數(shù)據(jù)

In Vitro:

DMF : 5 mg/mL (16.66 mM; Need ultrasonic; DMSO can inactivate Cisplatin's activity)

H₂O : 1 mg/mL (3.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.3328 mL	16.6639 mL	33.3278 mL
5 mM	0.6666 mL	3.3328 mL	6.6656 mL
10 mM	0.3333 mL	1.6664 mL	3.3328 mL

請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 儲存時，請在 6 個月內(nèi)使用，-20°C 儲存時，請在 1 個月內(nèi)使用。

In Vivo:

請根據(jù)您的實驗動物和給藥方式選擇適當?shù)娜芙夥桨浮Ｒ韵氯芙夥桨付颊埾劝凑?In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：

——為保證實驗結果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用；以下溶劑前顯示的百
分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

1.

請依序添加每種溶劑： 0.5% CMC-Na/saline water
Solubility: 20 mg/mL (66.66 mM); Suspended solution; Need ultrasonic
2.

請依序添加每種溶劑： 50% PEG300 50% saline
Solubility: 10 mg/mL (33.33 mM); Suspended solution; Need ultrasonic